Sallman, D. A., Foran, J. M., Watts, J. M., Stein, E., De Botton, S., Fathi, A. T., … Dinardo, C. D. (2022). Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Sallman, David Andrew, James M. Foran, Justin M. Watts, Eytan Stein, Stephane De Botton, Amir Tahmasb Fathi, Gabrielle T. Prince, et al. “Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Sallman DA, Foran JM, Watts JM, Stein E, De Botton S, Fathi AT, et al. Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Sallman, David Andrew, et al. “Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Sallman DA, Foran JM, Watts JM, Stein E, De Botton S, Fathi AT, Prince GT, Stone RM, Patel PA, Roboz GJ, Arellano ML, Erba HP, Pigneux A, Baratam P, Thomas XG, Bai X, Kapsalis SM, Garcia-Manero G, Dinardo CD. Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy. JOURNAL OF CLINICAL ONCOLOGY. 2022.